180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, will be participating at the Gordon Research Conference, which is slated for July 9–14, 2023. The presentation, which is titled “Physiological and Disease Relevance and Underlying Molecular Properties of Collagens,” will be presented by Professor Jagdeep Nanchahal. The conference will be held at Colby-Sawyer College in New London, New Hampshire. A professor of hand, plastic and reconstructive surgery at the University of Oxford and chairman of the clinical advisory board of 180 Life Sciences, Nanchahal will be reporting on his findings on Dupuytren’s disease. Nanchahal’s team has led the modern application of molecular and single-cell techniques to describe the cellular composition of early-stage Dupuytren’s nodules, and this analysis has provided key data regarding the signaling pathways that drive the progression of the disease. The research included identifying tumor necrosis factor (“TNF”) as a potential therapeutic target and identifying the optimal dose and formulation of adalimumab (an anti-TNF already approved for other conditions such as inflammatory arthritis). “The Gordon Research Conferences are very prestigious international events dating back to 1931, which are organized by a nonprofit organization to promote scientific discussion and progress, and build communities to advance the frontiers of science,” said 180 Life Sciences CEO Dr. James Woody in the press release. “Each conference is limited to 200 attendees; scientists must be selected by the conference chair to attend the meeting. All conferees are active participants in their community and contribute to moving the frontiers of the scientific field forward.”
To view the full press release, visit https://ibn.fm/1CBBo
About 180 Life Sciences Corp.
180 Life Sciences is a clinical-stage biotechnology company driving groundbreaking studies into clinical programs that are seeking to address major unmet medical needs. The company’s focus is a novel program to treat several inflammatory disorders using anti-TNF (tumor necrosis factor). For more information about the company, visit www.180LifeSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to ATNF are available in the company’s newsroom at https://ibn.fm/ATNF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork
